Russell William Jenkins

This study identifies a novel CD8+ TIL subset that uses lymphotoxin and IFN pathways to kill cancer cells, linking LTB expression to clinical response in melanoma.

This paper describes a designed IL-21 mimic, 21h10, which shows potent antitumor activity in multiple models and reduces toxicity through TNF blockade.

This study shows that targeting CD38 improves T cell function and restores response to immunotherapy in melanoma models.

The paper identifies CD43 as a glyco-immune checkpoint that inhibits human macrophage phagocytosis, showing that O-linked glycosylation and sialylation pathways regulate this process in AML.

The paper identifies CREB5 as a driver of immunotherapy resistance in melanoma by promoting collagen matrix deposition, which activates LAIR1 signaling on immune cells.

This study identifies LRP2 expression in melanoma as linked to a transient differentiation state, T cell infiltration, and IFNγ signaling, with associations to better prognostic features.

This study shows that delivering 4-1BBL via AAV enhances IL-12-induced anti-glioblastoma immunity in mouse models by boosting CD8 T cell activity and survival.

DrugMap quantitatively analyzes cysteine ligandability across 416 cancer cell lines, revealing redox state, conformational changes, and mutations as drivers of variability, and identifies covalent inhibitors targeting NFκB1 and SOX10.